drugset
drugset / Trial / NCT06221111

Comparison of Rimegepant and Placebo for Pain in IBS

NCT06221111 ↗

Phase 2 Completed 39 enrolled Mayo Clinic Pfizer · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary aim of this study is to evaluate the efficacy of rimegepant on abdominal pain scores in participants with non-constipation IBS.

Timeline

Start
2024-06-06
Primary completion
2025-05-30
Completion
2025-06-03

Outcome

Missed primary endpoint

registry analysis (superiority test); Rimegepant vs Placebo; p = 0.41; ANCOVA NCT06221111 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Rimegepant Small molecule 75 mg Oral

Indications

irritable bowel syndrome